New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Inclusion Criteria: * Antiretroviral therapy (ART) experienced and currently receiving a stable regimen containing 3 nucleoside reverse transcriptase inhibitors (NRTIs), or 2 NRTIs plus a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitors (NNRTI) for at least 3 months (there should be no significant ART modifications for at least 3 months and no ART change anticipated between Screening and initiation of the study therapy). * Patients must be naive to tenofovir. * HIV-1 RNA level \> 1000 copies/ml on at least one occasion within 21 days of study entry. * A CD4 cell count \> 50 cells/mm3. * Specified viral genotypes. Exclusion Criteria: * Pregnant or breast-feeding women. * Has an active diagnosis of AIDS. * Additional qualifying criteria to be determined by the physician.